• Publications
• Experience
• About

Professional Focus

Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT). Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures. Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer. Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.

Education

1988	University of Chicago	BA	Chemistry
1994	University of Chicago	PhD	Pathology
1996	University of Chicago	MD	Medicine
1996-1997	Kaiser Permanente Medical Center, Santa Clara, CA	Intern	Internal Medicine
1997-2001	UCSF	Resident	Radiation Oncology
01/00-04/00	UCSF	Chief Resident	Radiation Oncology

Professional Experience

2008-Present	UCSF	Director of the CyberKnife Radiosurgery Program
2008-Present	UCSF	Associate Professor
2007-2008	UCSF	Interim Director of the CyberKnife Radiosurgery Program
2001-2008	UCSF	Assistant Professor
1997-2001	UCSF	Residency in Radiation Oncology
1996-1997	Kaiser	Internal Medicine Internship

Awards & Honors

1984-1988	Dean's List; National Science Foundation Fellowship for undergraduate research in Chemistry; National Science Foundation Graduate Fellowship, Honorable Mention; Phi Beta Kappa; B.A. with General Honors
1988-1992	NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
1992-1994	NIH Training Grant, Department of Molecular Genetic & Cell Biology, University of Chicago, Chicago, IL
1994-1996	Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
1998-1999	NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
2000	RSNA Research & Education Foundation Roentgen Resident/Fellow Research Award
2001-2002	Clinical Investigator Research Program Recipient, University of California San Francisco
2002	Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD
2002-2003	UCSF Prostate Cancer SPORE Developmental Research Program Award
2002-2003	Co-investigator on UCSF Prostate Cancer SPORE, Project 3
2003-2005	RSNA Research Scholar Award
2003-2005	ASTRO Junior Faculty Award

Publications

Gottschalk AR, Joseph LJ, Quintáns J. Differential induction of Egr-1 expression in WEHI-231 sublines does not correlate with apoptosis. European Journal of Immunology 23(8): 2011-2015, 1993.

Gottschalk AR, McShan CL, Merino R, Nuñez G, Quintáns J. Physiological cell death in B lymphocytes: I. Differential susceptibility of WEHI-231 sublines to anti-Ig induced physiological cell death and lack of correlation with bcl-2 expression. International Immunology 6(1): 121-130, 1994.

Gottschalk AR, Joseph LJ, Quintáns J. FcgRII cross-linking inhibits anti-Ig-induced egr-1 and egr-2 expression in BCL1. Journal of Immunology 152(5): 2115-2122, 1994.

Gottschalk AR, Boise LH, Thompson CB, Quintáns J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proceedings of the National Academy of Sciences of the United States of America 91(15): 7350-7354, 1994.

Quintáns J, Kilkus J, McShan CL, Gottschalk AR, Dawson G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochemical and Biophysical Research Communications 202(2): 710-714, 1994.

Quintáns J., Bonn GA, McShan CL, Gottschalk AR. Studies on the induction of apoptosis in WEHI 231 cells by pharmacological agents and lipid mediators. Sphingosine and ceramide induce apoptosis in WEHI 231. Cell Death and Differentiation 1: 93-99, 1994.

Quintáns J, and Gottschalk AR. Life and death in lymphocytes: the ceramide connection. The Immunologist 2(6): 185-189, 1994.

Gottschalk AR, McShan CL, Kilkus J, Dawson G, Quintáns J. Resistance to anti-IgM-induced apoptosis in a WEHI-231 subline is due to insufficient production of ceramide. European Journal of Immunology 25(4): 1032-1038, 1995.

Choi MSK, Boise LH, Gottschalk AR, Quintáns J, Thompson CB, Klaus GGB. The role of bcl-xL in CD40-mediated rescue from anti-µ-induced apoptosis in WEHI-231 B lymphoma cells. European Journal of Immunology 25(5): 1352-1357, 1995.

Gottschalk AR, and Quintáns J. Apoptosis in B lymphocytes: the WEHI-231 perspective. Immunology and Cell Biology 73(1): 8-16, 1995.

Boise LH, Gottschalk AR, Quintáns J, Thompson CB. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Current Topics in Microbiology and Immunology 200: 107-121, 1995.

Gottschalk AR, Boise LH, Oltvai ZN, Accavitti MA, Korsmeyer SJ, Quintáns J, Thompson CB. The ability of Bcl-xL and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death and Differentiation. 3: 113-118, 1996.

Wiesner DA, Kilkus JP, Gottschalk AR, Quintáns J, Dawson G. Anti-immunoglobulin- induced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-xL. Journal of Biological Chemistry 272(15): 9868-9876, 1997.

Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 14(4): 391-396, 2000.

Gottschalk AR, Basila D, Wong M, Dean N, Brandts CH, Stokoe D, Haas-Kogan DA. p27kip1 is Required for PTEN-induced G1 arrest. Cancer Research 61(5): 2105-2110, 2001.

Ermoian RS, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, Haas-Kogan DA. Components of the PI3-kinase Signaling Pathway are Associated with Glioma Histology and Patient Survival. Clinical Cancer Research 8: 1100-1106, 2002.

Langen, KM, Pouliot, J, Anezinos, C, Aubin, M, Gottschalk, AR, Hsu, IC, Lowther, D, Liu, YM, Shinohara, K, Verhey, LJ, Weinberg, V and Roach, M. Evaluation of ultrasound-based prostate localization for image guided radiation therapy. International Journal of Radiation Oncology * Biology * Physics 57: 635-644, 2003.

Gottschalk AR and Roach M. The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomized trials. British Journal of Cancer 90(5): 950-4, 2004.

Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper R, Stokoe D, Haas-Kogan DA. PKB/Akt meditates radiosensitization by the signaling inhibitor LY294002 in human gliomas. Journal of Neuro-Oncology 71(3): 215-22, 2005.

Gottschalk AR, A. Doan A, Nakamura JL, D. A. Haas-Kogan DA and D. Stokoe D. Inhibition of phosphatidylinositol-3-kinase causes cell death through a PKB dependent mechanism and growth arrest through a PKB independent mechanism. International Journal of Radiation Oncology * Biology * Physics 61 (4): 1183-1188, 2005.

Master V, Gottschalk AR, Kane C and Carroll PR. Management of patients with isolated recurrence following radical nephrectomy. Journal of Urology 174: 473-477, 2005.

Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Shinohara K. Combined Modality Treatment with High Dose Rate Brachytherapy Boost for Locally Advanced Prostate Cancer. Brachytherapy 4: 202-206, 2005.

Gottschalk AR, A. Doan A, Nakamura JL, D. A. Haas-Kogan DA and D. Stokoe D. Inhibition of phosphotidylinositol-3-kinase causes increased sensitivity to radiation through a PKB dependent mechanism. International Journal of Radiation Oncology* Biology * Physics 63: 1221-7, 2005.

Tran QNH, Kim AC, Gottschalk AR, Wara WM, Phillips TL, O'Donnell RJ, James O. Johnston JO, Weinberg V, and Haas-Kogan DA. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma 2006: 1-6, 2006.

Schiffner D, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, His IC, Siniohara K and Roach M. Daily Electronic Portal Imaging of Implanted Gold Seed Fiducials in Patients Undergoing Salvage Radiotherapy After Radical Prostatectomy. International Journal of Radiation Oncology* Biology * Physics 67(2): 610-619, 2007.

Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, and Hsu IC. Feasibility of High Dose Rate (HDR) Brachytherapy Salvage for Local Prostate Recurrence After Radiotherapy: The UCSF Experience. International Journal of Radiation Oncology*Biology*Physics 67(4): 1106-1112, 2007.

Morin O, Gillis A, Descovich M, Chen J, Aubin M, Aubry JF, Chen H, Gottschalk AR, Xia P and Pouliot J. Patient dose considerations for megavoltage Cone-Beam CT Imaging. Medical Physics 34(5): 1819-27, 2007.

Chan L, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, and Roach M. Proposed rectal dose constraints for patients undergoing definitive whole-pelvis radiotherapy for clinically localized prostate cancer. International Journal of Radiation Oncology*Biology*Physics Mar 12, 2008.

Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, and Ma L. Simulated real time image guided intra-fraction tracking-delivery for hypofractionated prostate IMRT. Medical Physics 35: 4041-48, 2008.

Aubry JF, Cheung J, Morin O, Gottschalk A, Beaulieu L, Pouliot J. Correction of megavoltage cone-beam CT images of the pelvic region based on phantom measurements for dose calculation purposes. PMID 19223832 Journal of Applied Clinical Medical Physics 10(1):2852, 2009.

Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, and Shinohara K. Salvage permanent perineal radioactive seed implantation for the treatment of localized prostate adenocarcinoma recurrent after external beam radiation. PMID: 19245439 British Journal Urology International, February 23, 2009.

Cheung J, Aubry JF, Yom S, Gottschalk AR, Celi JC and Pouliot J. Dose recalculation and the dose-guided radiation therapy (DGRT) process using megavoltage cone-beam CT. PMID 19345518 International Journal of Radiation Oncology*Biology*Physics 74:583-92, 2009

Jabbari S, Weinberg VV, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, and Roach M. Equivalent Biochemical Control and Improved PSA Nadir Following Permanent Prostate Seed Implant Brachytherapy (PPI) Versus High-Dose Three Dimensional Conformal Radiotherapy (3DCRT) and High-Dose Conformal Proton Beam Radiotherapy Boost (CPBRTB). PMID 19409729. International Journal of Radiation Oncology*Biology*Physics April 29, 2009.

Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, McLaughlin Roach M 3^rd, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. PMID 19428310. Brachytherapy May 8, 2009.

Wu V, Aubin M, Bani-Hashemi A, Gangadharan B, Gottschalk AR, Morin O, Yom SS, and Faddegon B. High quality low dose con beam CT images of patents with a megavoltage imaging beam line. In press. International Journal of Radiation Oncology*Biology*Physics, 2009

Burk TF, Horvai AE, Gottschalk AR, Leong SPL, Law J, and O’Donnell RJ. Pediatric Patellar metastatic melanoma: case report and literature review. In press. American Journal of Orthopedics. 2009